Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Theralase TechnologiesTLTFF -1.67%46 Equity-to-Asset is 0.50 as of Mar. 2026, which is 28% below its 10-year median of 0.69. GuruFocus rates TLTFF with a GF Score™ of 46/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Theralase Technologies ranks worse than 67.29% on this metric.
The historical rank and industry rank for Theralase Technologies's Equity-to-Asset or its related term are showing as below:
TLTFF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18 Med: 0.69 Max: 0.95
Current: 0.5
During the past 13 years, the highest Equity to Asset Ratio of Theralase Technologies was 0.95. The lowest was 0.18. And the median was 0.69.
TLTFF's Equity-to-Asset is ranked worse than 67.29% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs TLTFF: 0.50
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Theralase Technologies Equity-to-Asset Related Terms
Theralase Technologies Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Theralase Technologies's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TLTFF vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Theralase Technologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Theralase Technologies's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies (TLTFF) has a Equity-to-Asset of 0.50 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Theralase Technologies and its competitors. This is 28% below median its historical median of 0.69. Over the past decade, Theralase Technologies' Equity-to-Asset has ranged from 0.18 to 0.95. According to the industry distribution chart, Theralase Technologies ranks #574 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 67.3%.
Is Theralase Technologies' Equity-to-Asset too high?
Theralase Technologies' current Equity-to-Asset of 0.50 is 28% below median its 10-year median of 0.69. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 0.95. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Theralase Technologies' value of 0.50 is 21.9% below this industry median. Based on the distribution chart, Theralase Technologies ranks #574 out of 853 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Theralase Technologies has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theralase Technologies ranks #574 out of 853 companies for Equity-to-Asset. This places Theralase Technologies in the lower half of its industry. The industry median Equity-to-Asset is 0.64. Theralase Technologies' value of 0.50 is 21.9% below this benchmark. Historically, Theralase Technologies' own Equity-to-Asset has ranged from 0.18 to 0.95 over the past decade. While the company's 10-year median is 0.69 vs. the industry median of 0.64, Theralase Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theralase Technologies's current Equity-to-Asset of 0.50 is 21.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Theralase Technologies and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theralase Technologies's current Equity-to-Asset is 0.50, which is 28% below median its own 10-year median of 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.20 — trading 54.1% above its estimated fair value. The current Equity-to-Asset is 0.50, which is 28% below median its 10-year median of 0.69 and 21.9% below the Medical Devices & Instruments industry median of 0.64. Theralase Technologies' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current Equity-to-Asset is 0.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TLTFF) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of $0.20 is trading 54.1% above its estimated GF Value™ of $0.13.
GuruFocus considers Theralase Technologies to be Significantly Overvalued.
Key valuation signals for TLTFF:
Equity-to-Asset: 0.50 (28% below median its 10-year median of 0.69)
GF Value™: $0.13 vs. price of $0.20 (54.1% above fair value)
Industry Position: 21.9% below the Medical Devices & Instruments median (#574 of 853)
No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
46GF Score
Get the complete analysis for TLTFF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLTFF has been successfully added to your 
